Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription


1 Am J Ther
1 ANZ J Surg
1 Appl Immunohistochem Mol Morphol
2 Biochem Biophys Res Commun
1 Biochim Biophys Acta Mol Cell Res
1 Biomarkers
1 BMC Cancer
1 Cancer Cytopathol
1 Clin Immunol
1 Clin Transl Med
1 Diagn Cytopathol
1 Environ Health Perspect
1 Eur Urol
2 Eur Urol Open Sci
1 Heliyon
1 IEEE Open J Eng Med Biol
1 Int Urol Nephrol
1 J Biomol Struct Dyn
1 J Clin Oncol
1 J Immunother Cancer
1 J Infus Nurs
1 J Urol
1 Onco Targets Ther
1 Oncologist
1 Pathol Res Pract
1 Pathology
4 Urol Oncol
1 Urologe A
3 World J Urol
1 Zhong Nan Da Xue Xue Bao Yi Xue Ban

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Ther

  1. KONALA VM, Adapa S, Aronow WS
    Immunotherapy in Bladder Cancer.
    Am J Ther. 2022;29:e334-e337.
    PubMed         Abstract available

    ANZ J Surg

  2. BADIANI S, MacDermid E, Rutland T, Turner C, et al
    Metastatic urothelial carcinoma to the colon presenting with pelvic abscess tracking to the right hip joint.
    ANZ J Surg. 2022;92:1229-1231.

    Appl Immunohistochem Mol Morphol

  3. KRISTOFFERSEN HL, Roge R, Nielsen S
    Comparison of Antibodies to Detect Uroplakin in Urothelial Carcinomas.
    Appl Immunohistochem Mol Morphol. 2022;30:326-332.
    PubMed         Abstract available

    Biochem Biophys Res Commun

  4. YONEYAMA MS, Yoneyama T, Tobisawa Y, Yamamoto H, et al
    TMEM2 expression is downregulated as bladder cancer invades the muscle layer.
    Biochem Biophys Res Commun. 2022;613:1-6.
    PubMed         Abstract available

  5. REN W, Ren J, Zhang N, Liu X, et al
    CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer.
    Biochem Biophys Res Commun. 2022;613:12-18.
    PubMed         Abstract available

    Biochim Biophys Acta Mol Cell Res

  6. LV M, Zhong Z, Huang M, Tian Q, et al
    Corrigendum to "lncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA" [Biochim. Biophys. Acta Mol. Cell Res. 1864 (2017) 1887-1899/BBAMCR-17-151R2].
    Biochim Biophys Acta Mol Cell Res. 2022;1869:119281.


  7. GRUBA N, Stachurski L, Lesner A
    Chemical tools to monitor bladder cancer progression.
    Biomarkers. 2022 May 9:1-41. doi: 10.1080/1354750X.2022.2076153.
    PubMed         Abstract available

    BMC Cancer

  8. DENG L, Chao H, Deng H, Yu Z, et al
    A novel and sensitive DNA methylation marker for the urine-based liquid biopsies to detect bladder cancer.
    BMC Cancer. 2022;22:510.
    PubMed         Abstract available

    Cancer Cytopathol

  9. MCINTIRE PJ, Aragao A, Burns BL, Pambuccian SE, et al
    Digital image analysis of high-grade urothelial carcinoma in urine cytology confirms chromasia heterogeneity and reveals a subset with hypochromatic nuclei and another with extremely dark or "India ink" nuclei.
    Cancer Cytopathol. 2022;130:363-369.
    PubMed         Abstract available

    Clin Immunol

  10. LI H, Ni M, Xue C, Li L, et al
    Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis.
    Clin Immunol. 2022;236:108927.
    PubMed         Abstract available

    Clin Transl Med

  11. WANG G, Zhang M, Zhang Y, Xie Y, et al
    NAT10-mediated mRNA N4-acetylcytidine modification promotes bladder cancer progression.
    Clin Transl Med. 2022;12:e738.
    PubMed         Abstract available

    Diagn Cytopathol

  12. MOULAVASILIS N, Stravodimos K, Meletis E, Levis P, et al
    The Paris system classification for urinary cytology in patients under bacillus Calmette-Guerin treatment.
    Diagn Cytopathol. 2022;50:289-294.
    PubMed         Abstract available

    Environ Health Perspect

  13. BEANE FREEMAN LE, Kogevinas M, Cantor KP, Villanueva CM, et al
    Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Case-Control Studies.
    Environ Health Perspect. 2022;130:57006.
    PubMed         Abstract available

    Eur Urol

  14. CONROY S, Nguyen AHT
    Compound to Clinic? A Preclinical High-throughput Screening Pathway To Expedite Drug Discovery in Bladder Cancer.
    Eur Urol. 2022 May 5. pii: S0302-2838(22)01811.

    Eur Urol Open Sci

  15. GROSSMANN NC, Rajwa P, Quhal F, Konig F, et al
    Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
    Eur Urol Open Sci. 2022;39:14-21.
    PubMed         Abstract available

  16. DE RUITER BM, van de Kamp MW, van Steenbergen JPZ, Franckena M, et al
    A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.
    Eur Urol Open Sci. 2022;39:7-13.
    PubMed         Abstract available


  17. INCE O, Yildiz H, Kisbet T, Erturk SM, et al
    Classification of retinoblastoma-1 gene mutation with machine learning-based models in bladder cancer.
    Heliyon. 2022;8:e09311.
    PubMed         Abstract available

    IEEE Open J Eng Med Biol

  18. CHO H, Tong F, You S, Jung S, et al
    Prediction of the Immune Phenotypes of Bladder Cancer Patients for Precision Oncology.
    IEEE Open J Eng Med Biol. 2022;3:47-57.
    PubMed         Abstract available

    Int Urol Nephrol

  19. TAKEN K, Aslan R, Eryilmaz R, Alp HH, et al
    Response to Letter to the Editor 'Serum irisin concentration in patients with bladder cancer'.
    Int Urol Nephrol. 2022;54:1247-1248.

    J Biomol Struct Dyn

  20. SHAH HD, Saranath D, Murthy V
    A molecular dynamics and docking study to screen anti-cancer compounds targeting mutated p53.
    J Biomol Struct Dyn. 2022;40:2407-2416.
    PubMed         Abstract available

    J Clin Oncol

  21. OWENS-WALTON J, Williams C, Rompre-Brodeur A, Pinto PA, et al
    Minority Enrollment in Phase II and III Clinical Trials in Urologic Oncology.
    J Clin Oncol. 2022;40:1583-1589.
    PubMed         Abstract available

    J Immunother Cancer

  22. YAN S, Zeng H, Jin K, Shao F, et al
    NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    J Immunother Cancer. 2022;10.
    PubMed         Abstract available

    J Infus Nurs

  23. WOOD LS, Conway D, Lapuente M, Salvador G, et al
    Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses.
    J Infus Nurs. 2022;45:142-153.
    PubMed         Abstract available

    J Urol

  24. ROSEN GH, Nallani A, Muzzey C, Murray KS, et al
    Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
    J Urol. 2022;207:1302-1311.
    PubMed         Abstract available

    Onco Targets Ther

  25. SCHULZ A, Loloi J, Pina Martina L, Sankin A, et al
    The Development of Non-Invasive Diagnostic Tools in Bladder Cancer.
    Onco Targets Ther. 2022;15:497-507.
    PubMed         Abstract available


  26. RAVI P, Ravi A, Riaz IB, Freeman D, et al
    Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.
    Oncologist. 2022;27:e406-e409.
    PubMed         Abstract available

    Pathol Res Pract

  27. YANG J, Qi F, Tan B, Dai G, et al
    circSPECC1 promotes bladder cancer progression via regulating miR-136-5p/GNAS axis.
    Pathol Res Pract. 2022;234:153914.
    PubMed         Abstract available


  28. YAMAMOTO Y, Takahara T, Ohashi A, Taniguchi N, et al
    Cytokeratin 5/6 expression in pT1 bladder cancer predicts intravesical recurrence in patients treated with bacillus Calmette-Guerin instillation.
    Pathology. 2022 May 5. pii: S0031-3025(22)00124.
    PubMed         Abstract available

    Urol Oncol

  29. YAMAMOTO S, Kato M, Takeyama Y, Yukimatsu N, et al
    A retrospective study on optimal number of cycles of the first-line platinum-based chemotherapy for metastatic urothelial carcinoma.
    Urol Oncol. 2022;40:194.
    PubMed         Abstract available

  30. GEYNISMAN DM, Broughton E, Hao Y, Zhang Y, et al
    Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.
    Urol Oncol. 2022;40:195.
    PubMed         Abstract available

  31. SHARMA G, Krishna M, Pareek T, Bora GS, et al
    Current practice patterns in the perioperative management of patients undergoing radical cystectomy: Results from a global survey.
    Urol Oncol. 2022;40:196.
    PubMed         Abstract available

  32. JAVIER-DESLOGES J, Nelson TJ, Murphy JD, McKay RR, et al
    An evaluation of trends in the representation of patients by age, sex, and diverse race/ethnic groups in bladder and kidney cancer clinical trials.
    Urol Oncol. 2022;40:199.
    PubMed         Abstract available

    Urologe A

    [Extended vs. standard lymphadenectomy for the treatment of urothelial carcinoma of the bladder in patients undergoing radical cystectomy].
    Urologe A. 2022;61:530-533.

    World J Urol

  34. XIA QD, Hu J, Liu Z, Li C, et al
    Can artificial intelligence help reduce unnecessary bladder biopsies? Comment on "Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary".
    World J Urol. 2022;40:1241-1242.

  35. O'SULLIVAN S, Janssen M, Holzinger A, Nevejans N, et al
    Explainable artificial intelligence (XAI): closing the gap between image analysis and navigation in complex invasive diagnostic procedures.
    World J Urol. 2022;40:1125-1134.
    PubMed         Abstract available

  36. SONG Y, Du Y, Qin C, Xu T, et al
    Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report".
    World J Urol. 2022;40:1251-1252.

    Zhong Nan Da Xue Xue Bao Yi Xue Ban

  37. ZHONG M, Jiang F, Song L, Nie M, et al
    MiR-133b regulates the proliferation, colony formation, and invasion of bladder cancer cells via inhibiting SOX4.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022;47:407-415.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.